Related Experiment Video

Updated: Nov 5, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.6K

MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis

Anand Singh1, Nathanael Pruett1, Roma Pahwa2

  • 1Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Molecular Therapy. Nucleic Acids
|May 17, 2021
PubMed

Insights

MicroRNA-206 (miR-206) is downregulated in malignant pleural mesothelioma (MPM) and suppresses tumor growth by targeting the Ras pathway. Combining miR-206 with abemaciclib shows therapeutic promise for MPM.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options.
  • The Ras signaling pathway is crucial for MPM proliferation but lacks targeted therapies.
  • MicroRNAs (miRNAs) are implicated in cancer pathobiology and can regulate signaling networks.

Purpose of the Study:

  • To investigate the role of miR-206 in MPM.
  • To evaluate the therapeutic potential of restoring miR-206 in MPM.
  • To identify novel therapeutic strategies for MPM.

Main Methods:

  • Analysis of miR-206 expression in patient samples and cell lines.
  • In vivo studies using MPM tumor xenograft models in mice.
  • Assessment of cell cycle arrest and signaling pathway modulation.
  • Evaluation of combination therapy with abemaciclib.

Main Results:

  • miR-206 is significantly downregulated in MPM tissues.
  • Restored miR-206 expression induces cell death by suppressing Ras pathway components, including CDK6.
  • miR-206 re-expression causes G1/S cell cycle arrest.
  • Combination therapy with abemaciclib and miR-206 demonstrates additive efficacy and improves survival in preclinical models.

Conclusions:

  • miR-206 plays a critical role in MPM pathogenesis and acts as a tumor suppressor.
  • Targeting the Ras pathway via miR-206 restoration is a viable therapeutic strategy for MPM.
  • Combination therapy involving miR-206 and abemaciclib warrants further clinical investigation for MPM treatment.
Keywords:
Rascell cyclemesotheliomamicroRNAreceptor tyrosine kinase

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.8K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.6K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.6K